

BUDESONIDE orodispersible tablets (Jorveza® ▼) for eosinophilic oesophagitis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of BUDESONIDE orodispersible tablets (Jorveza® ▼) for eosinophilic oesophagitis

GREY

Budesonide 1mg orodispersible tablets are licensed for the treatment of eosinophilic oesophagitis in adults (older than 18 years of age).¹

This recommendation will be reviewed when the [NICE TA](#) is published. This is expected to be in October 2019.

In the meantime, treatment of eosinophilic oesophagitis should continue to follow local pathways.

References

1. Dr. Falk Pharma UK Ltd. Summary of Product Characteristics [Jorveza 1mg orodispersible tablet](#), 08 January 2018. Accessed online 25 March 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.